Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Liabilities: 2019-2024

Historic Total Liabilities for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $142.3 million.

  • Nurix Therapeutics' Total Liabilities rose 9.85% to $150.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $150.2 million, marking a year-over-year increase of 9.85%. This contributed to the annual value of $142.3 million for FY2024, which is 8.22% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Total Liabilities of $142.3 million as of FY2024, which was down 8.22% from $155.1 million recorded in FY2023.
  • Nurix Therapeutics' 5-year Total Liabilities high stood at $155.1 million for FY2023, and its period low was $106.1 million during FY2020.
  • For the 3-year period, Nurix Therapeutics' Total Liabilities averaged around $136.8 million, with its median value being $142.3 million (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 98.02% in 2020, then decreased by 15.92% in 2022.
  • Nurix Therapeutics' Total Liabilities (Yearly) stood at $106.1 million in 2020, then grew by 26.77% to $134.5 million in 2021, then decreased by 15.92% to $113.1 million in 2022, then skyrocketed by 37.18% to $155.1 million in 2023, then decreased by 8.22% to $142.3 million in 2024.